Key Takeaways

GHRP-6 can acutely stimulate growth hormone release in controlled human experiments.
That is the real scientific anchor. It does not automatically follow that repeated compounded injections improve muscle, fat loss, recovery, appetite, sleep, or aging outcomes.
The most honest description is an unapproved ghrelin-receptor agonist with established short-term endocrine activity and unresolved chronic therapeutic, formulation, and safety questions.

‍

[Bowers et al., 1990; Popovic et al., 2000; FDA, 2026]

‍

GHRP-6: an unapproved synthetic six-amino-acid growth hormone secretagogue and ghrelin-receptor agonist with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2; human studies establish acute endocrine activity, not chronic wellness, body-composition, recovery, appetite, sleep, or longevity efficacy.

Overview

The central scientific and compliance problem with GHRP-6 is not whether the molecule has ever been administered to humans. It has. Small human studies from the late 1980s through the 2010s show that acute GHRP-6 exposure can provoke growth hormone release, interact strongly with endogenous growth hormone-releasing hormone physiology, alter ACTH and cortisol under some experimental conditions, and generate measurable intravenous pharmacokinetics. The problem is evidence transfer: those endocrine challenge and diagnostic studies are routinely rewritten as proof that repeated compounded subcutaneous GHRP-6 builds muscle, reduces fat, accelerates recovery, improves sleep, treats poor appetite, or slows aging. The reviewed evidence does not support that jump. [Ilson et al., 1989; Bowers et al., 1990; Frieboes et al., 1995; Popovic et al., 2000; Cabrales et al., 2013]

Molecule identity is another load-bearing issue. GHRP-6 is a synthetic amidated hexapeptide containing D-tryptophan and D-phenylalanine; it is not endogenous ghrelin, not growth hormone, not growth hormone-releasing hormone, and not interchangeable with GHRP-2, hexarelin, ipamorelin, macimorelin, ibutamoren, or CJC-1295. It acts through the growth hormone secretagogue receptor, now commonly called the ghrelin receptor, but sharing a receptor family or a marketing category does not make these compounds clinically equivalent. [NCATS Inxight Drugs, 2026; Howard et al., 1996; Kojima et al., 1999]

The current U.S. regulatory posture is cautionary. GHRP-6 has no FDA-approved indication. FDA lists it in 503A Category 3, meaning it was nominated without adequate support, and in 503B Category 2, meaning the agency has identified potential significant safety risks for outsourcing-facility compounding. FDA specifically cites potential immunogenicity related to aggregation and peptide-related impurities, limited safety information, possible cortisol effects, and increased blood glucose associated with decreased insulin sensitivity. A historical orphan-drug designation for pediatric growth failure was withdrawn or revoked and never became FDA approval. [FDA, 2025; FDA, 2026; FDA Orphan Drug Database, 2026]

What it is

GHRP-6 is short for growth hormone-releasing peptide-6 and is also called growth hormone-releasing hexapeptide, Hexapeptide-2, SK&F-110679, or SKF-110679. NCATS lists the sequence as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. The parent or free-base substance has formula C46H56N12O6, molecular weight about 873 Da, CAS 87616-84-0. [NCATS Inxight Drugs, 2026; PubChem, 2026]

The peptide is fully synthetic rather than a naturally occurring human hormone. Historical reviews describe GHRPs as met-enkephalin-related scaffolds modified with D-amino acids to create growth hormone secretagogue activity while eliminating opioid activity. GHRP-6 therefore should not be framed as "replacing a peptide the body already makes." Its endogenous receptor ligand is ghrelin, which was identified years after GHRP molecules had already been synthesized and studied. [Bowers et al., 1984; Howard et al., 1996; Kojima et al., 1999; Berlanga-Acosta et al., 2017]

GHRP-6 evidence must stay molecule-specific. GHRP-2 has more appetite and clinical-development literature in some settings; hexarelin is an optimized analogue; ipamorelin has a different selectivity profile; macimorelin is a distinct diagnostic ghrelin-receptor agonist; and CJC-1295 is a GHRH analogue acting through a different receptor. None of those evidence streams can be silently credited to GHRP-6. [Howard et al., 1996; Kojima et al., 1999; FDA, 2026]

Material	What it is	Why it cannot be collapsed into "GHRP-6"
Endogenous ghrelin	Acylated stomach-derived hormone and endogenous receptor ligand.	Receptor sharing does not establish identical potency, tissue distribution, appetite effects, PK, or safety. [Kojima et al., 1999]
Growth hormone	191-amino-acid pituitary hormone downstream of secretagogue signaling.	Direct GH replacement and secretagogue-induced GH pulses are different interventions with different evidence and risks.
GHRH / somatorelin	Endogenous hypothalamic releasing hormone acting at the GHRH receptor.	GHRP-6 has no sequence identity with GHRH and acts through the ghrelin receptor; acute synergy does not make them one drug. [Bowers et al., 1990; Howard et al., 1996]
GHRP-2 / pralmorelin	Related but distinct ghrelin-receptor agonist.	Different sequence, endocrine selectivity, human evidence, and safety record. FDA evaluates it separately. [FDA, 2026]
Hexarelin / ipamorelin / ibutamoren / macimorelin	Other peptide or non-peptide growth hormone secretagogues.	Class membership does not confer molecule-specific efficacy, dose, route, or safety evidence.
CJC-1295 + GHRP-6 blend	Commercial combination of a GHRH analogue and GHRP-6.	Acute GHRH/GHRP-6 synergy in challenge studies does not validate this specific blend, chronic schedule, dose ratio, or clinical outcome. [Bowers et al., 1990]

How it's proposed to work

The most defensible mechanistic anchor is agonism at the growth hormone secretagogue receptor type 1a, now commonly called the ghrelin receptor. The receptor was cloned from pituitary and hypothalamic tissue in 1996, and ghrelin was identified as its endogenous ligand in 1999. GHRP-6 predates that discovery and is best understood as a synthetic ghrelin-receptor agonist rather than as a fragment of ghrelin itself. [Howard et al., 1996; Kojima et al., 1999]

At the pituitary level, GHRP-6 can stimulate somatotroph growth hormone release. Human studies show an acute, dose-related GH response and a response substantially larger when GHRP-6 is administered with GHRH than when either agent is given alone. That synergy is physiologically informative: the two compounds engage complementary signaling systems. It is not, by itself, evidence that a chronic CJC-1295/GHRP-6 product improves body composition, recovery, or sleep. [Ilson et al., 1989; Bowers et al., 1990; Peñalva et al., 1993]

The hypothalamus is also important. Patients with hypothalamic-pituitary disconnection showed blunted GHRP-6 responses and loss of GHRP-6/GHRH synergy, while later work using a GHRH antagonist concluded that endogenous hypothalamic GHRH is required for maximal GH stimulation. [Popovic et al., 1995; Pandya et al., 1998]

GHRP-6 signaling is not perfectly selective for GH. Small human sleep studies reported acute effects on ACTH and cortisol as well as sleep EEG, and FDA now specifically identifies potential cortisol effects and increased blood glucose related to reduced insulin sensitivity as safety concerns. Those findings make broad "hormone optimization" language especially misleading: an intervention that drives one desired endocrine pulse may perturb other axes at the same time. [Frieboes et al., 1995; Frieboes et al., 1999; FDA, 2026]

A separate preclinical literature attributes GH-independent cytoprotective, anti-inflammatory, myocardial, and organ-protection effects to GHRP-6. Some animal models reported reduced myocardial necrosis or multiple-organ injury, and newer engineered-delivery work continues that line. These are useful mechanistic and development hypotheses, but they remain species-, model-, route-, and formulation-specific. [Cibrián et al., 2006; Berlanga et al., 2007; Berlanga-Acosta et al., 2017; Zhao et al., 2026]

Common forms in circulation

FDA's current 503A nomination document names GHRP-6 in Category 3, without attaching a validated route or formulation. The 503B document and the agency's safety-risk page list GHRP-6 in Category 2, again as a bulk drug substance rather than an approved finished product. FDA's historical warning letters document compounded GHRP-6 injection products, including a sermorelin/GHRP-6 injection recalled after a sterility failure, while emphasizing that GHRP-6 was not a component of an approved drug and did not qualify for 503A exemptions. [FDA, 2017; FDA, 2019; FDA, 2025; FDA, 2026]

Current market pages show lyophilized vials, pre-mixed presentations, nasal sprays, research kits with syringes or bacteriostatic water, and blends with CJC-1295. [Weiss Wellness + Beauty, n.d.; Kane Orthopedic Institute, 2026; Peptide Works, n.d.; Pure Bio Labs, n.d.]

Names and aliases

Scientific and legacy names include GHRP-6, GHRP6, growth hormone-releasing peptide-6, growth hormone-releasing hexapeptide, Hexapeptide-2, SK&F-110679, SKF-110679, and the sequence shorthand His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. "GHRP" by itself is a class label and should not be treated as molecule-specific. [NCATS Inxight Drugs, 2026; FDA Orphan Drug Database, 2026]

Common pairings include GHRP-6 plus CJC-1295 with or without DAC, GHRP-6 plus sermorelin, and broader "GH secretagogue" programs that rotate among ipamorelin, hexarelin, GHRP-2, and GHRP-6. The scientifically legitimate observation is that GHRP-6 and native GHRH can show acute synergy. The unsupported step is converting that observation into a validated chronic commercial stack, dose ratio, route, or outcome. [Bowers et al., 1990; Peptide Works, n.d.]

Regulatory status

GHRP-6 has no FDA-approved human indication. The FDA orphan-drug database records a May 23, 1990 designation for long-term treatment of children with growth failure due to inadequate endogenous GH secretion, sponsored by SmithKline Beecham. The same record states that the designation was withdrawn or revoked and that the product was not FDA-approved for the orphan indication. [FDA Orphan Drug Database, 2026]

For traditional 503A pharmacy compounding, FDA's May 14, 2026 nomination document places GHRP-6 in Category 3: "bulk drug substances nominated without adequate support." Category 3 is not a permissive list and not an approval pathway. [FDA, 2017; FDA, 2019; FDA, 2026]

For 503B outsourcing facilities, FDA's March 21, 2025 nomination document lists GHRP-6 in Category 2: "bulk drug substances that raise significant safety risks." FDA's current safety-risk page explains the concern in molecule-specific terms: potential immunogenicity for certain routes because of aggregation and peptide-related impurities; limited safety information; possible cortisol effects; and increased blood glucose due to decreased insulin sensitivity. [FDA, 2025; FDA, 2026]

In 2017, FDA documented a voluntary recall of a sermorelin/GHRP-6 injection after sterility failure and separately concluded that the firm's GHRP-6 products did not meet 503A conditions. That event does not prove all compounded GHRP-6 is contaminated; it does demonstrate that route, facility practices, sterility, and finished-product controls are independent safety questions. [FDA, 2017]

Safety

Human therapeutic safety has not been established for chronic compounded GHRP-6 use. The strongest current regulator-facing concerns are immunogenicity related to aggregation and peptide impurities, limited overall safety information, potential cortisol effects, and increased blood glucose associated with decreased insulin sensitivity. [FDA, 2026]

The acute human literature adds endocrine nuance. GHRP-6 can alter ACTH and cortisol in some settings, and GH-axis stimulation can influence glucose handling, fluid balance, and IGF-1 exposure. Small, single-dose studies cannot define the incidence or clinical importance of those effects under repeated use, in older adults, in people with diabetes, in patients with sleep apnea, or in multi-peptide stacks. [Frieboes et al., 1995; Frieboes et al., 1999; FDA, 2026]

Product-quality risk remains separate from pharmacology. Contemporary reporting on the broader peptide gray market describes mislabeled, under- or overfilled, and impure products, while FDA warning letters document sterility failures and inadequate compounding controls in real facilities. [FDA, 2017; The Guardian, 2026]

Purported benefits, by evidence

Purported benefit	What the evidence supports	What it does not support	Source
Acute GH release / "hormone optimization"	Multiple small controlled human studies show that GHRP-6 can acutely stimulate GH release and can act synergistically with GHRH.	"Optimizes hormones," "restores youthful GH," or proves clinical benefit from repeated home use.	[Ilson et al., 1989; Bowers et al., 1990; Peñalva et al., 1993]
GH-deficiency testing / growth treatment	GHRP-6/GHRH combinations were explored diagnostically, and GHRP-6 received a historical pediatric growth-failure orphan designation.	"FDA-approved for growth hormone deficiency," "treats short stature," or chronic pediatric efficacy. The designation was withdrawn/revoked and never approved.	[Popovic et al., 2000; FDA Orphan Drug Database, 2026]
Lean muscle gain / strength	GH-axis stimulation makes the claim biologically intuitive, and clinic pages market it for muscle and performance.	Any claim that GHRP-6 has been shown to increase lean mass, strength, or performance in controlled human trials.	[Weiss Wellness + Beauty, n.d.]
Fat loss / body recomposition	Market pages connect GHRP-class therapy to fat metabolism and body composition.	"Burns visceral fat," "reduces adiposity," "body-recomposition peptide," or general weight-loss efficacy in humans.	[Weiss Wellness + Beauty, n.d.]
Appetite stimulation / cachexia	GHRP-6 is a ghrelin-receptor agonist, and current market pages associate it with increased appetite.	A validated treatment for anorexia, cachexia, cancer weight loss, frailty, or poor intake. GHRP-2 and other ghrelin-agonist data do not transfer automatically.	[Kojima et al., 1999]
Sleep / "deep sleep"	A small study reported route-dependent changes in sleep EEG and nocturnal GH, ACTH, and cortisol after acute GHRP-6.	"Treats insomnia," "improves restorative sleep," or durable subjective sleep benefit.	[Frieboes et al., 1995; Frieboes et al., 1999]
Recovery / tendon / joint healing	Preclinical cytoprotection and clinic recovery language create plausibility.	"Heals tendons," "repairs joints," "speeds postoperative recovery," or human injury-recovery efficacy.	[Berlanga-Acosta et al., 2017]
Cardioprotection / organ protection	Animal studies reported reduced myocardial necrosis and protection in severe organ-injury models.	Prevention or treatment of myocardial infarction, kidney injury, sepsis, or multiple-organ failure in people.	[Cibrián et al., 2006; Berlanga et al., 2007; Zhao et al., 2026]
Healthy aging / longevity	The claim appears in anti-aging and peptide-market framing.	"Anti-aging peptide," "extends lifespan," "reverses aging," or "promotes longevity" as a clinically established outcome.	[Time, 2026]

Key literature

Ilson BE, Jorkasky DK, Curnow RT, Stote RM. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab. 1989;69(1):212-214. Direct same-molecule evidence that GHRP-6 can acutely stimulate GH release in healthy people.

Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. Same-molecule GH response and marked acute synergy with native GHRH.

Frieboes RM, Murck H, Antonijevic IA, Steiger A. Effects of GHRP-6 on nocturnal GH, ACTH and cortisol secretion and sleep EEG in man: role of routes of administration. J Neuroendocrinol. 1999;11(6):473-478. Route-dependent acute endocrine and sleep-EEG effects.

Popovic V, Leal A, Micic D, et al. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults. Lancet. 2000;356(9236):1137-1142. Supports GHRH/GHRP-6 as an endocrine diagnostic challenge in adults.

Cabrales A, Gil J, Fernández E, et al. Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 in nine male healthy volunteers. Eur J Pharm Sci. 2013;48(1-2):40-46. Measured intact-peptide disposition after a defined IV bolus in nine men.

References

U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act. Updated March 21, 2025.
U.S. Food and Drug Administration. Search Orphan Drug Designations and Approvals: His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, designation 46190. Accessed July 16, 2026.
U.S. Food and Drug Administration. Town and Country Compounding and Consultation Services, LLC, Warning Letter 518371. October 17, 2017.
NCATS Inxight Drugs. Hexapeptide-2 (GHRP-6), UNII 4H7N4I6X6A. Accessed July 16, 2026.
World Anti-Doping Agency. 2026 Prohibited List, S2 Peptide Hormones, Growth Factors, Related Substances, and Mimetics. Effective January 1, 2026.
The Guardian. "Traceability is vital": labs test thousands of unregulated substances amid peptide craze. April 6, 2026; and UK becoming "wild west" for experimental peptides, expert warns. July 12, 2026.
Time. What to Know About the "Anti-Aging" Peptide Shots Flooding Social Media. February 24, 2026.

GHRP-6